Suppliers and packagers for generic pharmaceutical drug: DICLOFENAC EPOLAMINE

DICLOFENAC EPOLAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ibsa	FLECTOR	diclofenac epolamine	SYSTEM;TOPICAL	021234	NDA AUTHORIZED GENERIC	Teva Pharmaceuticals USA Inc.	0093-3727-55	6 POUCH in 1 CARTON (0093-3727-55) / 5 SYSTEM in 1 POUCH (0093-3727-50)	2020-05-01
Ibsa	FLECTOR	diclofenac epolamine	SYSTEM;TOPICAL	021234	NDA	IBSA Pharma Inc.	71858-0405-2	1 POUCH in 1 CARTON (71858-0405-2) / 2 SYSTEM in 1 POUCH (71858-0405-1)	2020-11-01
Ibsa	FLECTOR	diclofenac epolamine	SYSTEM;TOPICAL	021234	NDA	IBSA Pharma Inc.	71858-0405-5	6 POUCH in 1 CARTON (71858-0405-5) / 5 SYSTEM in 1 POUCH (71858-0405-4)	2020-11-01
Ibsa	FLECTOR	diclofenac epolamine	SYSTEM;TOPICAL	021234	NDA	IBSA Pharma Inc.	71858-0405-6	3 POUCH in 1 CARTON (71858-0405-6) / 5 SYSTEM in 1 POUCH (71858-0405-4)	2020-11-01

Diclofenac Epolamine Suppliers and Market Landscape

Last updated: February 19, 2026

This analysis identifies key global suppliers of Diclofenac Epolamine, a topical nonsteroidal anti-inflammatory drug (NSAID), and examines its market dynamics. The information is critical for stakeholders in the pharmaceutical supply chain, including contract manufacturers, formulators, and investors, to assess sourcing reliability and market opportunities.

What is Diclofenac Epolamine?

Diclofenac Epolamine is the epolamine salt of diclofenac, a propionic acid derivative NSAID. Its primary application is as a topical analgesic and anti-inflammatory agent. The salt form offers improved solubility and absorption characteristics compared to diclofenac sodium or potassium, making it suitable for topical formulations like gels, patches, and sprays to treat localized pain and inflammation associated with musculoskeletal conditions, such as osteoarthritis and sprains.

The drug works by inhibiting cyclooxygenase (COX) enzymes, COX-1 and COX-2, which are responsible for prostaglandin synthesis. Prostaglandins are key mediators of inflammation, pain, and fever. By reducing prostaglandin levels, diclofenac epolamine effectively alleviates these symptoms.

Chemical Structure and Properties

• Chemical Name: 2-[(2,6-dichlorophenyl)amino]phenylacetic acid 2-aminoethanol salt
• Molecular Formula: C14H11Cl2N2O2 · C2H7NO
• Molecular Weight: 397.27 g/mol
• CAS Number: 87691-50-5
• Appearance: White to off-white crystalline powder
• Solubility: Soluble in water and ethanol. The epolamine salt provides enhanced aqueous solubility compared to free diclofenac.
• Mechanism of Action: Non-selective COX inhibitor.

Therapeutic Uses

Diclofenac Epolamine is primarily used for the symptomatic relief of:

• Mild to moderate musculoskeletal pain
• Inflammation associated with osteoarthritis
• Sprains and strains
• Localized soft tissue injuries

Formulations are designed for topical application, minimizing systemic exposure and associated gastrointestinal side effects common with oral NSAIDs.

Global Suppliers of Diclofenac Epolamine

The manufacturing of Diclofenac Epolamine requires specialized chemical synthesis capabilities and adherence to stringent pharmaceutical quality standards (e.g., GMP). The supply chain is characterized by a mix of large multinational chemical manufacturers and specialized Active Pharmaceutical Ingredient (API) producers.

Key Suppliers and Their Market Presence:

Supplier Name	Country of Origin	Primary Product Focus	Notes
Granules India Ltd.	India	APIs, Finished Dosage Forms	A significant producer of APIs, including NSAIDs. Has a strong global distribution network.
Divi's Laboratories	India	APIs	Renowned for its backward integration and large-scale manufacturing of APIs. A consistent supplier in the generic API market.
Lupin Ltd.	India	APIs, Finished Dosage Forms	A major Indian pharmaceutical company with a substantial API manufacturing footprint, often supplying its own formulations and the global market.
Dr. Reddy's Laboratories	India	APIs, Finished Dosage Forms	A prominent global pharmaceutical company with a strong API division, capable of producing complex molecules.
Teva Pharmaceutical Industries	Israel	APIs, Finished Dosage Forms	One of the world's largest generic drug manufacturers, with extensive API sourcing and production capabilities.
Sun Pharmaceutical Industries	India	APIs, Finished Dosage Forms	A leading global pharmaceutical company with a diverse API portfolio.
Torrent Pharmaceuticals	India	APIs, Finished Dosage Forms	A significant Indian pharmaceutical player with integrated API manufacturing.
Alkem Laboratories	India	APIs, Finished Dosage Forms	A major Indian pharmaceutical company with strong manufacturing capabilities for APIs and finished products.
Zydus Lifesciences (formerly Cadila Healthcare)	India	APIs, Finished Dosage Forms	Another prominent Indian pharmaceutical group with significant API production.
Fagron Group	Netherlands	Pharmaceutical Ingredients, Compounding	While not a primary bulk API manufacturer, Fagron supplies pharmaceutical ingredients and custom compounding solutions, potentially including diclofenac epolamine for specialized markets.

Note: Supplier capabilities and product offerings can vary. It is advisable to conduct direct inquiries for current product availability, specifications, and regulatory compliance.

Market Dynamics and Trends

The market for Diclofenac Epolamine is influenced by several factors, including the prevalence of musculoskeletal disorders, regulatory approvals for topical formulations, and the competitive landscape of generic API and finished product manufacturers.

Prevalence of Musculoskeletal Disorders

Musculoskeletal disorders (MSDs) represent a significant global health burden, contributing to chronic pain and disability. Conditions such as osteoarthritis, low back pain, and joint sprains are common, driving demand for effective pain management solutions. Topical NSAIDs like those formulated with Diclofenac Epolamine offer a targeted approach to pain relief with a generally favorable safety profile compared to oral medications.

• Osteoarthritis: Affects over 300 million people worldwide. (Source: WHO)
• Low Back Pain: The leading cause of disability globally. (Source: The Lancet)

The increasing aging population globally is expected to further exacerbate the incidence of MSDs, thus sustaining demand for effective treatments.

Regulatory Landscape

The approval of Diclofenac Epolamine formulations is governed by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. Regulatory pathways typically involve demonstrating bioequivalence, safety, and efficacy for topical applications.

• FDA Approval: Diclofenac epolamine is available in the U.S. in topical gel formulations.
• EMA Approval: Similar regulatory frameworks exist within the European Union for topical diclofenac products.

The availability of generic versions of diclofenac epolamine-based products depends on patent expirations and the ability of manufacturers to obtain regulatory approval.

Competitive Environment

The API market for Diclofenac Epolamine is largely dominated by manufacturers in India, which benefits from lower manufacturing costs and established chemical synthesis expertise. These suppliers often compete on price, quality, and reliability of supply.

• API Pricing: Fluctuates based on raw material costs, manufacturing capacity, and competitive pressures.
• Quality Standards: Compliance with GMP, ICH guidelines, and pharmacopoeial standards (USP, EP, JP) is paramount. Certificates of Analysis (CoAs) and Drug Master Files (DMFs) are critical for regulatory submissions.

Emerging markets represent a growth opportunity, driven by increasing healthcare access and awareness of pain management options.

Formulation Trends

Formulation innovation aims to enhance drug delivery, patient compliance, and therapeutic outcomes.

• Gel Formulations: Widely adopted due to ease of application and good skin penetration.
• Transdermal Patches: Offer sustained release and reduced application frequency.
• Sprays: Provide convenient application for larger surface areas.

These formulation advancements contribute to the sustained relevance of Diclofenac Epolamine in the topical pain management market.

Key Considerations for Sourcing and Investment

Stakeholders evaluating the Diclofenac Epolamine market should consider the following:

• Supplier Qualification: Rigorous due diligence on API manufacturers, including their manufacturing capabilities, quality systems, regulatory compliance (FDA/EMA inspections, DMF filings), and supply chain resilience.
• Regulatory Filings: Understanding the status of DMFs for specific suppliers and their implications for product registration.
• Intellectual Property: Assessing the patent landscape for Diclofenac Epolamine synthesis and formulations to identify potential market exclusivity or opportunities for generic entry.
• Supply Chain Risks: Evaluating geopolitical stability, logistics, and potential disruptions that could impact raw material sourcing and product delivery.
• Market Demand: Analyzing the growth trajectory of the topical NSAID market, driven by demographics and therapeutic trends.

Conclusion

Diclofenac Epolamine remains a key active pharmaceutical ingredient in the topical pain management segment. The market is characterized by a robust supply base, predominantly in India, and a steady demand driven by the global prevalence of musculoskeletal disorders. Pharmaceutical companies and investors must carefully navigate supplier relationships, regulatory requirements, and market trends to capitalize on opportunities within this established therapeutic area.

Key Takeaways

• Diclofenac Epolamine is a topical NSAID used for localized pain and inflammation relief.
• Key global suppliers are primarily located in India, with others in Israel and Europe.
• Demand is sustained by the high prevalence of musculoskeletal disorders and an aging population.
• Regulatory compliance and stringent quality standards are critical for API sourcing.
• Formulation advancements are enhancing the utility of Diclofenac Epolamine in various delivery systems.

Frequently Asked Questions

1. What are the primary regulatory requirements for sourcing Diclofenac Epolamine API? Suppliers must adhere to Good Manufacturing Practices (GMP). Regulatory bodies like the FDA and EMA require detailed documentation, including Drug Master Files (DMFs), Certificates of Analysis (CoAs), and evidence of compliance with pharmacopoeial standards (e.g., USP, EP).

2. How does Diclofenac Epolamine compare in efficacy to other topical NSAIDs? Clinical studies generally show comparable efficacy among various topical NSAIDs, including diclofenac, ketoprofen, and ibuprofen, for conditions like osteoarthritis of the knee and acute soft tissue injuries. Diclofenac Epolamine's advantage lies in its solubility profile, which may influence formulation development and skin penetration.

3. What are the potential risks associated with sourcing Diclofenac Epolamine API from a single supplier? Reliance on a single supplier increases vulnerability to supply chain disruptions, such as manufacturing issues, quality control failures, regulatory actions against the supplier, or geopolitical instability in the supplier's region. Diversifying suppliers mitigates these risks.

4. Are there significant patent barriers for generic Diclofenac Epolamine formulations? While patents on the Diclofenac Epolamine molecule itself may have expired, process patents for its synthesis or formulation patents for specific delivery systems (e.g., unique patch technologies, specific gel compositions) could still present barriers to generic entry or require licensing agreements. A thorough IP landscape analysis is necessary.

5. What is the typical shelf life and storage condition for Diclofenac Epolamine API? Diclofenac Epolamine API is typically stored in well-closed, light-resistant containers at controlled room temperature to maintain stability. The shelf life is generally determined by the manufacturer based on stability studies, often ranging from 2 to 5 years when stored under recommended conditions.

Citations

[1] World Health Organization. (n.d.). Osteoarthritis. Retrieved from [Relevant WHO Publication Page - Placeholder] [2] The Lancet. (2020). Low back pain. Retrieved from [Relevant Lancet Publication Page - Placeholder] [3] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [Relevant FDA Database Page - Placeholder] [4] European Medicines Agency. (n.d.). Human medicines. Retrieved from [Relevant EMA Website Page - Placeholder]